Oestrogen receptors were one of the first molecular markers of prognosis to be described in breast cancer and 10 years ago we reported our experience of their significance in predicting early recurrence of disease following surgical treatment (Cooke et al., 1979) . In that study we found the presence of oestrogen receptors to be associated with both longer disease free interval and overall survival. Although our results were similar to those of several other studies (Knight et al., 1977; Allegra et al., 1979; Westerberg et al., 1980; Gapinski et al., 1980) , the finding in. some later studies were inconsistent and areas of controversy have arisen. A minority of investigators failed to find any survival advantage for oestrogen receptor positive patients (Hilf et al., 1980; Alanko et al., 1984; Parl et al., 1984) . In those studies in which a survival advantage has been reported for patients with oestrogen receptor positive tumours three broad areas of disagreement have emerged. These have related to the duration of time over which oestrogen receptors exert any beneficial effect, the sub-groups of patients benefiting and whether the apparently longer survival of oestrogen receptor positive patients was due to a prolonged disease free survival or longer post recurrence survival.
Oestrogen receptors were one of the first molecular markers of prognosis to be described in breast cancer and 10 years ago we reported our experience of their significance in predicting early recurrence of disease following surgical treatment (Cooke et al., 1979) . In that study we found the presence of oestrogen receptors to be associated with both longer disease free interval and overall survival. Although our results were similar to those of several other studies (Knight et al., 1977; Allegra et al., 1979; Westerberg et al., 1980; Gapinski et al., 1980) , the finding in. some later studies were inconsistent and areas of controversy have arisen. A minority of investigators failed to find any survival advantage for oestrogen receptor positive patients (Hilf et al., 1980; Alanko et al., 1984; Parl et al., 1984) . In those studies in which a survival advantage has been reported for patients with oestrogen receptor positive tumours three broad areas of disagreement have emerged. These have related to the duration of time over which oestrogen receptors exert any beneficial effect, the sub-groups of patients benefiting and whether the apparently longer survival of oestrogen receptor positive patients was due to a prolonged disease free survival or longer post recurrence survival.
As studies with longer follow-up than in the initial reports appeared the apparent improvement in survival amongst receptor positive patients in some studies was only present for a limited period, thereafter the survival of the two groups being similar (Raemaekers et al., 1985; Von Maillot et al., 1982; Hahnel et al., 1979; Howat et al., 1983) . Although some studies found that both disease free interval and overall prognosis were prolonged in receptor positive patients (Bishop et al., 1979; Osborne et al., 1980; Rich et al., 1978) others only noted an improvement in post-relapse survival (Hahnel et al., 1979; Hilf et al., 1980; Howell et al., 1984) and concluded that receptor status had only identified which patients were most likely to benefit from hormonal manipulation (Howell et al., 1984; Andry et al., 1989; Howat et al., 1985) . Finally, other reports found improved survival only in certain sub-groups of patients, such as post-menopausal women or patients with axillary nodal involvement (Vollenweider-Zerargui et al., 1986; Bishop et al., 1979; Kinne et al., 1981 Figures 1 and 2 illustrate the relationship of oestrogen receptor status to survival, both individually and also stratified by nodal status. Women with oestrogen receptor positive tumours tended to have a better prognosis, but this was not statistically significant (X2 = 2.90; ldf; P = 0.09). Figure 2 suggests that any effect is confined to node positive patients, but the formal test of interaction does not support such a subgroup effect (P = 0.58), which can be explained by chance..
Multivariate analysis
Both nodal status and tumour size were powerful independent prognostic factors, but controlling for these oestrogen receptors failed to achieve statistical significance. Table II summarises the results of the Cox regression with these variables.
Discussion
The results of this study indicate that oestrogen receptor status has no long term prognostic value in women with Figure 2 Survival for patients stratified by both nodal and oestrogen receptor status. operable breast cancer whereas the traditional markers of tumour size and nodal status remained so. These observations are similar to those of other recent studies (Andry et al., 1989; Spyratos et al., 1989) as is the observation that prognostic significance recedes with time (Howell et al., 1984; Hahnel et al., 1979; Howat et al., 1983; Andry et al., 1989; Spyratos et al., 1989) . These results contrast with the findings of our own earlier observations and those of other workers, particularly in the inability of receptor status to separate out a group of poor risk node negative patients. One explanation for this may be that earlier studies tended to use disease recurrence as their end point.
I
When many of the earlier studies were carried out it was hoped that knowledge of receptor status would be of value in determining the most appropriate treatment for individual patients (Croton et al., 1981; Cooke et al., 1979) . However, receptor evaluation was only possible in selected laboratories and routine determination was not widely adopted. Development of immunocytochemical techniques capable of determining receptor status has meant that evaluation of this factor can now be carried out routinely on tumour specimens by most laboratories. This method, for the most part, provides equivalent results to those determined by ligand binding techniques: (King et al., 1985; Hawkins et al., 1986) . The use of this technique has been advocated in elderly patients in order to select those most. suitable for tamoxifen treatment alone (Gaskell et al., 1989; Coombes et al., 1987) . Despite this, routine clinical determination of receptor status has been questioned in light of the published data relating receptor status to survival (Barnes et al., 1989) . Our findings support this scepticism, but this does not diminish the value of determining receptor status in the context of research.
Despite their weak general prognostic ability, oestrogen receptors represent a measurable entity, and therefore they are of potential value in assessing new drug treatment regimens by providing a constant factor to which response can be related. From the scientific view point several questions remain to be answered about the biological significance of this group of receptors.
Studies on the molecular structure of the receptor have indicated that even small changes in structure interfere with receptor function such that a tumour with positive receptor status may fail to behave as though the receptor were functioning. This distinction into 'activated' and 'non-activated' receptors has been shown to correlate well with clinical behaviour of tumours (White et al., 1987) . It has also been shown that quantification of oestrogen receptor may be more important than simple knowledge of receptor status (Shek et al., 1989) . Therefore, despite the failure of oestrogen receptors to establish a routine clinical role further studies are needed to determine their biological significance. 
